Disc Medicine, Inc. (NASDAQ:IRON - Free Report) - Equities research analysts at Wedbush boosted their FY2024 earnings per share estimates for shares of Disc Medicine in a report released on Monday, November 4th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($3.92) per share for the year, up from their previous estimate of ($3.94). Wedbush has a "Outperform" rating and a $75.00 price objective on the stock. The consensus estimate for Disc Medicine's current full-year earnings is ($4.09) per share. Wedbush also issued estimates for Disc Medicine's Q4 2024 earnings at ($0.89) EPS, Q1 2025 earnings at ($0.92) EPS, Q2 2025 earnings at ($0.95) EPS, Q3 2025 earnings at ($0.98) EPS, Q4 2025 earnings at ($1.01) EPS, FY2025 earnings at ($3.86) EPS, FY2026 earnings at ($3.96) EPS, FY2027 earnings at ($1.62) EPS and FY2028 earnings at $6.85 EPS.
Disc Medicine (NASDAQ:IRON - Get Free Report) last released its quarterly earnings results on Thursday, August 8th. The company reported ($1.03) EPS for the quarter, beating the consensus estimate of ($1.11) by $0.08.
IRON has been the topic of a number of other research reports. Cantor Fitzgerald reiterated an "overweight" rating and set a $85.00 price target on shares of Disc Medicine in a research report on Tuesday, October 15th. Raymond James raised Disc Medicine from an "outperform" rating to a "strong-buy" rating and upped their target price for the stock from $66.00 to $110.00 in a research note on Monday. Wells Fargo & Company started coverage on shares of Disc Medicine in a research note on Thursday, August 22nd. They issued an "overweight" rating and a $75.00 price target on the stock. Scotiabank upped their price objective on shares of Disc Medicine from $62.00 to $70.00 and gave the stock a "sector outperform" rating in a research report on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and set a $70.00 price objective on shares of Disc Medicine in a report on Tuesday. Nine analysts have rated the stock with a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Disc Medicine has an average rating of "Buy" and an average price target of $80.20.
Check Out Our Latest Report on Disc Medicine
Disc Medicine Stock Up 0.0 %
Shares of NASDAQ:IRON traded up $0.02 during trading on Wednesday, reaching $64.80. 534,671 shares of the company's stock traded hands, compared to its average volume of 355,865. Disc Medicine has a fifty-two week low of $25.60 and a fifty-two week high of $77.60. The company has a 50-day simple moving average of $49.06 and a 200-day simple moving average of $43.19. The firm has a market cap of $1.93 billion, a PE ratio of -18.01 and a beta of 0.60.
Insider Activity at Disc Medicine
In related news, Director William Richard White sold 7,136 shares of the stock in a transaction that occurred on Monday, November 4th. The stock was sold at an average price of $58.61, for a total value of $418,240.96. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. In the last quarter, insiders sold 7,538 shares of company stock valued at $437,875. Corporate insiders own 4.24% of the company's stock.
Institutional Investors Weigh In On Disc Medicine
A number of hedge funds have recently modified their holdings of IRON. Amalgamated Bank boosted its holdings in Disc Medicine by 76.9% in the 2nd quarter. Amalgamated Bank now owns 568 shares of the company's stock valued at $26,000 after purchasing an additional 247 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Disc Medicine by 45.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,075 shares of the company's stock valued at $54,000 after buying an additional 337 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in Disc Medicine in the second quarter valued at approximately $129,000. SG Americas Securities LLC grew its position in Disc Medicine by 44.2% in the second quarter. SG Americas Securities LLC now owns 4,071 shares of the company's stock worth $183,000 after acquiring an additional 1,247 shares during the period. Finally, ProShare Advisors LLC acquired a new stake in Disc Medicine during the first quarter worth $211,000. Hedge funds and other institutional investors own 83.70% of the company's stock.
About Disc Medicine
(
Get Free Report)
Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.
See Also
Before you consider Disc Medicine, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Disc Medicine wasn't on the list.
While Disc Medicine currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
